A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
Clinical trial NCT05766501 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05766501
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-17
- Primary completion
- 2025-10-16
- Enrollment
- 641
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.